The Role of miRNA in Group 3 Pulmonary Hypertension

Active, not recruiting

• Conditions: Pulmonary Hypertension

• Registration Number: NCT06714136
• Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Brief Summary

This study recognizes the substantial value of lung tissue obtained from explanted lungs for fundamental research purposes.By analyzing pulmonary tissue affected by pulmonary hypertension, it is possible to discover shared pathogenetic mechanisms between these two groups and to gain a deeper understanding of the mechanisms underlying pulmonary hypertension.

Detailed Description

Lung transplantation serves as the sole therapeutic approach targeting the enhancement of life expectancy and quality of life for individuals afflicted with advanced parenchymal or vascular lung diseases. The current study aligns with this objective, recognizing the substantial value of lung tissue obtained from explanted lungs for fundamental research purposes. By investigating lung tissue affected by both group 3 and group 1 pulmonary hypertension, it becomes possible to uncover shared pathogenic mechanisms between these two groups and gain a more profound understanding of the underlying mechanisms driving group 3 pulmonary hypertension. Furthermore, delving into the cells responsible for the expression of dysregulated miRNAs offers the potential to identify novel target mechanisms for the clinical management of group 3 pulmonary hypertension, an area currently limited in therapeutic options. Through a comparative analysis of the quantitative expression patterns of each miRNA among distinct groups, it becomes feasible to determine the extent of involvement of specific pathogenic pathways in the various forms of pulmonary hypertension. Consequently, this approach provides guidance for future research, directing focus towards the most relevant mechanisms of interest.

Study Timeline

• Study Start: 2022-10-10
• Primary Completion: 2023-12-20
• Status Verified: 2024-11
• Study First Submitted: 2024-11-28
• Study First Submitted QC: 2024-11-28
• Study First Posted: 2024-12-03
• Last Update Submitted: 2024-12-03
• Last Update Posted: 2024-12-05
• Study Completion: 2024-12-20

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
miRNAs espression	18 months	expression of miRNAs underlying the development of pulmonary arterial hypertension shared between idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.

Trial Locations

Locations (1)

IRCCS AOU Bologna; 🇮🇹 Bologna, Italy